485 related articles for article (PubMed ID: 30391662)
1. The pharmacological management of Lennox-Gastaut syndrome and critical literature review.
Verrotti A; Striano P; Iapadre G; Zagaroli L; Bonanni P; Coppola G; Elia M; Mecarelli O; Franzoni E; Liso P; Vigevano F; Curatolo P
Seizure; 2018 Dec; 63():17-25. PubMed ID: 30391662
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and tolerability of pharmacologic treatment options for Lennox-Gastaut syndrome.
Montouris GD; Wheless JW; Glauser TA
Epilepsia; 2014 Sep; 55 Suppl 4():10-20. PubMed ID: 25284033
[TBL] [Abstract][Full Text] [Related]
3. Current and emerging pharmacotherapy for the treatment of Lennox-Gastaut syndrome.
Besag FMC; Vasey MJ; Chin RFM
Expert Opin Pharmacother; 2023; 24(11):1249-1268. PubMed ID: 37212330
[TBL] [Abstract][Full Text] [Related]
4. Lennox-Gastaut syndrome: a comprehensive review.
Asadi-Pooya AA
Neurol Sci; 2018 Mar; 39(3):403-414. PubMed ID: 29124439
[TBL] [Abstract][Full Text] [Related]
5. Expert opinion: Proposed diagnostic and treatment algorithms for Lennox-Gastaut syndrome in adult patients.
Montouris G; Aboumatar S; Burdette D; Kothare S; Kuzniecky R; Rosenfeld W; Chung S
Epilepsy Behav; 2020 Sep; 110():107146. PubMed ID: 32563898
[TBL] [Abstract][Full Text] [Related]
6. Management of Lennox-Gastaut syndrome beyond childhood: A comprehensive review.
Samanta D
Epilepsy Behav; 2021 Jan; 114(Pt A):107612. PubMed ID: 33243685
[TBL] [Abstract][Full Text] [Related]
7. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial.
Thiele EA; Marsh ED; French JA; Mazurkiewicz-Beldzinska M; Benbadis SR; Joshi C; Lyons PD; Taylor A; Roberts C; Sommerville K;
Lancet; 2018 Mar; 391(10125):1085-1096. PubMed ID: 29395273
[TBL] [Abstract][Full Text] [Related]
8. Indirect comparison of clobazam and other therapies for Lennox-Gastaut syndrome.
Cramer JA; Sapin C; François C
Acta Neurol Scand; 2013 Aug; 128(2):91-9. PubMed ID: 23410109
[TBL] [Abstract][Full Text] [Related]
9. Lennox-Gastaut syndrome: New treatments and treatments under investigation.
Auvin S
Rev Neurol (Paris); 2020 Jun; 176(6):444-447. PubMed ID: 32409177
[TBL] [Abstract][Full Text] [Related]
10. Evaluating fenfluramine hydrochloride as an oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome.
Besag FMC; Vasey MJ; Chin RFM
Expert Rev Neurother; 2024 Mar; 24(3):235-249. PubMed ID: 38315124
[TBL] [Abstract][Full Text] [Related]
11. Lennox-Gastaut syndrome. Management update.
Al-Banji MH; Zahr DK; Jan MM
Neurosciences (Riyadh); 2015 Jul; 20(3):207-12. PubMed ID: 26166587
[TBL] [Abstract][Full Text] [Related]
12. Expanding the Treatment Landscape for Lennox-Gastaut Syndrome: Current and Future Strategies.
Strzelczyk A; Schubert-Bast S
CNS Drugs; 2021 Jan; 35(1):61-83. PubMed ID: 33479851
[TBL] [Abstract][Full Text] [Related]
13. Rufinamide for the treatment of Lennox-Gastaut syndrome: evidence from clinical trials and clinical practice.
Striano P; McMurray R; Santamarina E; Falip M
Epileptic Disord; 2018 Feb; 20(1):13-29. PubMed ID: 29313492
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results.
Laux LC; Bebin EM; Checketts D; Chez M; Flamini R; Marsh ED; Miller I; Nichol K; Park Y; Segal E; Seltzer L; Szaflarski JP; Thiele EA; Weinstock A;
Epilepsy Res; 2019 Aug; 154():13-20. PubMed ID: 31022635
[TBL] [Abstract][Full Text] [Related]
15. Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies.
Strzelczyk A; Schubert-Bast S
CNS Drugs; 2022 Oct; 36(10):1079-1111. PubMed ID: 36194365
[TBL] [Abstract][Full Text] [Related]
16. [Antiepileptic drugs in North America].
Akiyama T; Otsubo H
Brain Nerve; 2010 May; 62(5):519-26. PubMed ID: 20450099
[TBL] [Abstract][Full Text] [Related]
17. Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society.
Kanner AM; Ashman E; Gloss D; Harden C; Bourgeois B; Bautista JF; Abou-Khalil B; Burakgazi-Dalkilic E; Llanas Park E; Stern J; Hirtz D; Nespeca M; Gidal B; Faught E; French J
Neurology; 2018 Jul; 91(2):82-90. PubMed ID: 29898974
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Lennox-Gastaut syndrome.
Hancock EC; Cross JH
Cochrane Database Syst Rev; 2013 Feb; 2013(2):CD003277. PubMed ID: 23450537
[TBL] [Abstract][Full Text] [Related]
19. An evaluation of clobazam tablets and film (AQST-120) for the treatment of Lennox-Gastaut syndrome.
Besag FMC; Vasey MJ
Expert Opin Pharmacother; 2019 Sep; 20(13):1563-1574. PubMed ID: 31373526
[No Abstract] [Full Text] [Related]
20. Efficacy and safety of rufinamide as adjunctive therapy in patients with Lennox Gastaut syndrome: A systematic review and Meta-analysis.
Sharawat IK; Panda PK; Panda P; Dawman L
Seizure; 2021 Oct; 91():296-307. PubMed ID: 34273668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
